Fig. 3

ZFX controls the expression of WNT3 in CML CD34⁺ cells. A The heatmap shows the differentially expressed transcripts (fold-change > 2 and P < 0.05) between ZFX-silenced CML CD34⁺ cells and control cells (n = 3). B The relative expression of WNT3 was assessed by RT–qPCR in other ZFX-silenced CML CD34⁺ cells versus control cells (n = 5). C The expression of both ZFX and WNT3 was measured in ZFX-silenced K562 cells versus control cells (n = 3). D Western blotting was conducted to analyze the expression of ZFX and WNT3 in ZFX-silenced and control K562 cells. The secreted protein from ZFX-silenced K562 cells and control cells was analyzed by western blotting. To monitor the sample loading, Ponceau S staining was performed. E The expression of WNT3 was analyzed by RT–qPCR in CD34⁺ cells from normal bone marrow (NBM) of healthy donors (n = 8), CML patients in chronic phase (CP, n = 10), and those in blast crisis (BC, n = 5). Pt, patient. Data are presented as the mean ± SEM, and Student’s t-test was used to estimate the P-values (*P < 0.05 and **P < 0.01)